ESR2 and ovarian neoplasm: We have also demonstrated that selective activation of ERβ is additive to cisplatin and paclitaxel in the inhibition of ovarian tumor cell growth and that ERβ has a dominant cell regulatory effect over ERα, even in the presence of E2.